Eribulin is the first halichondrin-class microtubule dynamics inhibitor. With its 19 chiral centers capable of producing 219 isomers, it is the most complex non-peptide drug and is known as the "Mount Everest" of chemical synthesis. Eribulin possesses a unique microtubule-based antitumor mechanism of action, inhibiting microtubule growth and elongation, thereby preventing tumor cell division and ultimately leading to apoptosis. Additionally, eribulin induces vascular remodeling effects, improves the tumor microenvironment, enhances drug perfusion, increases the antitumor activity of sequential therapies, and ameliorates the immune microenvironment. It is indicated for the treatment of patients with locally recurrent or metastatic breast cancer who have previously received at least two chemotherapy regimens, including anthracyclines and taxanes. Authoritative guidelines such as the NCCN Breast Cancer Guidelines, ESO/ESMO ABC5 Guidelines, Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines, and the Chinese Anti-Cancer Association Guidelines and Norms for Breast Cancer Diagnosis and Treatment all recommend eribulin as a preferred chemotherapy drug for advanced breast cancer.

Kerilin®Eribulin Mesylate Injection was approved by NMPA on January 14, 2025. It is the second drug for breast cancer launched by Qingfeng Pharmaceutical Group following Palbociclib Capsules. Having passed the generic drug consistency evaluation, it is therapeutically equivalent to the originator product with a more favorable price, providing breast cancer patients with more treatment options.